Suscripción a Biblioteca: Guest

Nitric Oxide−Releasing Hybrid Drugs Target Cellular Processes Through S-Nitrosylation

Volumen 3, Edición 2, 2012, pp. 97-108
DOI: 10.1615/ForumImmunDisTher.2012006099
Get accessGet access

SINOPSIS

Nitric oxide (NO)−releasing agents such as JS-K and NO−releasing hybrids such as NO− and NONO−nonsteroidal anti-inflammatory drugs are novel agents with great potential for controlling cancer. Although studied extensively, a key question pertaining to their molecular targets and mechanism of action remains unclear: the role of NO in the overall biological effect of these agents. It has been shown that NO can directly modify sulfhydryl residues of proteins through S-nitrosylation and induce apoptosis. We showed that 3 structurally diverse NO−nonsteroidal anti-inflammatory drugs S-nitrosylated nuclear factor-κ p65 in vitro and in vivo and also showed that these agents S-nitrosylated caspase-3 in vivo. JS-K reduced nuclear β-catenin and cyclin D1 protein levels without affecting cytosolic β-catenin expression. On the basis of a time course study, S-nitrsolyation of nuclear β-catenin was determined to precede its degradation. These data provide a mechanistic role for NO and a rationale for the chemopreventive effects of these novel agents.

CITADO POR
  1. Iyer Anand Krishnan V., Rojanasakul Yon, Azad Neelam, Nitrosothiol signaling and protein nitrosation in cell death, Nitric Oxide, 42, 2014. Crossref

  2. Gorelenkova Miller Olga, Mieyal John J., Sulfhydryl-mediated redox signaling in inflammation: role in neurodegenerative diseases, Archives of Toxicology, 89, 9, 2015. Crossref

  3. Molina Marisa Nile, Ferder León, Manucha Walter, Emerging Role of Nitric Oxide and Heat Shock Proteins in Insulin Resistance, Current Hypertension Reports, 18, 1, 2016. Crossref

  4. Kashfi Khosrow, Esmaili Mahnoush, NO-H 2 S-Releasing Chimeras as a Multifaceted Approach to Cancer Therapy, in Nitric Oxide as a Chemosensitizing Agent, 2017. Crossref

  5. Guenzle Jessica, Wolf Louisa J, Garrelfs Nicklas W C, Goeldner Jonathan M, Osterberg Nadja, Schindler Cora R, Saavedra Joseph E, Weyerbrock Astrid, ATF3 reduces migration capacity by regulation of matrix metalloproteinases via NFκB and STAT3 inhibition in glioblastoma, Cell Death Discovery, 3, 1, 2017. Crossref

  6. Kashfi Khosrow, Duvalsaint Pascale L., Nitric Oxide Donors and Therapeutic Applications in Cancer, in Nitric Oxide Donors, 2017. Crossref

  7. Kashfi Khosrow, Vannini Federica, Nitric Oxide and Cancer: To Inhibit or To Induce iNOS: That Is the Question?, in Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders, 2019. Crossref

  8. Scicinski Jan, Kashfi Khosrow, Cancer and Beyond: Discovery and Development of NO-Releasing Therapeutics, in Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders, 2019. Crossref

  9. Sharma Vandana, Fernando Veani, Letson Joshua, Walia Yashna, Zheng Xunzhen, Fackelman Daniel, Furuta Saori, S-Nitrosylation in Tumor Microenvironment, International Journal of Molecular Sciences, 22, 9, 2021. Crossref

  10. Bahadoran Zahra, Mirmiran Parvin, Bahmani Mehrnoosh, Ghasemi Asghar, Potential Applications of Nitric Oxide Donors in Type 2 Diabetes, in The Role of Nitric Oxide in Type 2 Diabetes, 2022. Crossref

Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain